Obalon Therapeutics Inc (NASDAQ:OBLN) has earned an average recommendation of “Hold” from the six research firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $10.88.
OBLN has been the topic of a number of analyst reports. Zacks Investment Research raised Obalon Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a research note on Thursday, January 11th. BTIG Research reissued a “buy” rating and issued a $15.00 price target on shares of Obalon Therapeutics in a research note on Thursday, November 16th. UBS Group cut their price target on Obalon Therapeutics from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. Finally, Northland Securities reissued a “sell” rating and issued a $4.00 price target on shares of Obalon Therapeutics in a research note on Friday, November 3rd.
Obalon Therapeutics (OBLN) opened at $7.90 on Tuesday. The company has a market capitalization of $137.79 and a price-to-earnings ratio of -4.09. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.78 and a quick ratio of 8.65. Obalon Therapeutics has a 12-month low of $6.53 and a 12-month high of $13.18.
Several hedge funds have recently bought and sold shares of the company. C WorldWide Group Holding A S lifted its stake in shares of Obalon Therapeutics by 13.7% in the 3rd quarter. C WorldWide Group Holding A S now owns 276,211 shares of the company’s stock valued at $2,632,000 after purchasing an additional 33,318 shares during the period. Vanguard Group Inc. lifted its stake in shares of Obalon Therapeutics by 8.3% in the 2nd quarter. Vanguard Group Inc. now owns 170,266 shares of the company’s stock valued at $1,687,000 after purchasing an additional 13,108 shares during the period. Granite Investment Partners LLC acquired a new stake in Obalon Therapeutics during the 3rd quarter worth $1,036,000. Northern Trust Corp raised its stake in Obalon Therapeutics by 109.8% during the 2nd quarter. Northern Trust Corp now owns 92,237 shares of the company’s stock worth $914,000 after buying an additional 48,268 shares during the period. Finally, Royal Bank of Canada raised its stake in Obalon Therapeutics by 6.7% during the 2nd quarter. Royal Bank of Canada now owns 91,499 shares of the company’s stock worth $907,000 after buying an additional 5,732 shares during the period. 44.05% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Obalon Therapeutics Inc (OBLN) Given Consensus Rating of “Hold” by Brokerages” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.com-unik.info/2018/01/16/obalon-therapeutics-inc-obln-given-consensus-rating-of-hold-by-brokerages.html.
Obalon Therapeutics Company Profile
Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.
Receive News & Ratings for Obalon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.